Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

90 enrolled

Breast

Breast Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

28 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1 Active not recruiting

10 enrolled

Breast

Breast Neoplasms

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

Phase 1 Active not recruiting

197 enrolled

Other solid neoplasm

Solid Tumors

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Phase 1 Active not recruiting

159 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT04197713 2025-10-20

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Phase 1 Active not recruiting

13 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

70 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Selumetinib and Olaparib in Solid Tumors

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase I Comparative Bioavailability Study

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

BISCAY

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

COD

LuPARP

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

ORCA-2